Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drug Information Medical Encyclopedia Dictionary News Directories Other Resources

 

Medical Encyclopedia

Other encyclopedia topics:  A-Ag  Ah-Ap  Aq-Az  B-Bk  Bl-Bz  C-Cg  Ch-Co  Cp-Cz  D-Di  Dj-Dz  E-Ep  Eq-Ez  F  G  H-Hf  Hg-Hz  I-In  Io-Iz  J  K  L-Ln  Lo-Lz  M-Mf  Mg-Mz  N  O  P-Pl  Pm-Pz  Q  R  S-Sh  Si-Sp  Sq-Sz  T-Tn  To-Tz  U  V  W  X  Y  Z  0-9 

Fanconi's anemia

Printer-friendly versionEmail this page to a friend
Contents of this page:

Illustrations

Formed elements of blood
Formed elements of blood

Alternative names    Return to top

Anemia - Fanconi's; FA

Definition    Return to top

Fanconi's anemia is an inherited disease that primarily affects the bone marrow, resulting in decreased production of all types of blood cells. The lack of white blood cells predisposes the patient to infections, while the lack of platelets and red blood cells may result in bleeding, and fatigue (anemia), respectively. It is also associated with a broad variety of physical anomalies.

Fanconi's anemia is distinct from Fanconi's syndrome, a rare kidney disorder in which nutrients are lost through the urine.

Causes, incidence, and risk factors    Return to top

Fanconi's anemia is inherited in an autosomal recessive fashion, thus one copy of an abnormal gene is passed on by each parent. It occurs in all racial and ethnic groups. It is classically diagnosed between 2 and 15 years of age.

The disease is caused by a genetic defect that prevents cells from fixing damaged DNA or removing toxic, oxygen-free radicals that damage cells. Patients may be suspected of having the disease, if they have particular birth defects or develop decreased blood counts.

Symptoms    Return to top

This set of physical abnormalities occur in 80% of the cases:

Other potential symptoms:

Signs and tests    Return to top

Common tests performed for evaluation of Fanconi's anemia include:

Treatment    Return to top

If the hematological changes are mild to moderate and the patient does not require transfusions, a period of observation is currently recommended with frequent blood count checks and yearly bone marrow examinations. Observations for the development of secondary malignancies are also performed. In the short term, growth factors (such as erythropoetin, G-CSF, and GM-CSF) can be used to improve blood counts. Other growth factors for platelet stimulation are currently under investigation.

Bone marrow transplantation can cure the blood count problems associated with Fanconi's anemia. A HLA matched sibling is the best donor source, although umbilical cord blood cells and unrelated bone marrow can also be used. This therapy is very effective, and although there are associated toxicities, there has been improvement in the care of Fanconi patients during the transplant. There is approximately a 70% success rate for those patients fortunate enough to have a donor.

Even though a successful bone marrow transplant can cure the bone marrow problems from Fanconi's anemia, patients are at risk for other cancers and must be regularly followed by a physician (see below).

Prior to bone marrow transplantation, androgen therapy (oxymetholone, nandrolone decanoate) combined with low doses of steroids (hydrocortisone, prednisone) was the standard treatment, and this approach is currently used if the patient does not have an appropriate bone marrow donor. Typically, 50-75% of patients initially respond to androgen therapy, however, all patients will rapidly relapse when the drug is stopped. In most cases, these drugs eventually become ineffective.

Symptoms due to low blood counts, such as bleeding, infections, or symptomatic anemia (fatigue, shortness of breath, chest pain, dizziness), are treated with transfusions or antibiotics as needed. Patients with low neutrophil counts, who develop a fever, are usually treated with intravenous antibiotics.

Most patients visit a hematologist, an endocrinologist, and an ophthalmologist regularly. An orthopedist, gynecologist, or nephrologist may be seen as needed.

Expectations (prognosis)    Return to top

The reported survival of patients with Fanconi's anemia is highly varied, ranging from 2 to 25 years. The prognosis is especially poor if blood counts are low. Survival has likely been improved with the development and refinement of therapies, such as bone marrow transplantation.

Although bone marrow transplantation can restore blood counts, patients with Fanconi's anemia remain predisposed to a variety of cancers (leukemia, myelodysplastic syndrome, liver cancer, and others).

Women with Fanconi's anemia who become pregnant should be closely followed by a physician as they often require transfusions throughout pregnancy. Fertility is decreased in males, although a small number of Fanconi patients have fathered children.

Prevention    Return to top

Fanconi's anemia is an inherited disorder, and little can be done to prevent the disease short of genetic counseling for families known to be affected as a result. However, some complications, such as pneumococcal pneumonia, hepatitis, and varicella infections, can be prevented by vaccination.

Additionally, patients should avoid known carcinogens and undergo regular cancer screening to detect malignancies early in their course, should they arise.

Update Date: 10/28/2003

Updated by: Ezra E. W. Cohen, M.D., Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL. Review provided by VeriMed Healthcare Network.

adam.com logo

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2002 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.